OIE Reference Laboratory Reports Activities

Activities in 2019

This report has been submitted : 2020-01-07 12:22:24

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Classical swine fever
Address of laboratory:	New Haw, Addlestone Surrey KT15 3NB Weybridge UNITED KINGDOM
Tel.:	+44-208 026 9665
Fax:	
E-mail address:	helen.crooke@apha.gov.uk
Website:	https://www.gov.uk/government/organisations/animal-and-plant-health-agency
Name (including Title) of Head of Laboratory (Responsible Official):	Mr Chris Hadkiss Chief Executive
Name (including Title and Position) of OIE Reference Expert:	Dr Helen Crooke Head of Swine fever and pestivirus research
Which of the following defines your laboratory? Check all that apply:	Governmental Research

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
CSF Antibody ELISA	YES	3039	116
CSF antibody NPLA	YES	1	
Direct diagnostic tests		Nationally	Internationally
CSFV/ASF PCR	Yes	28	

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
WH303	Virus isolation ELISA	119	0	*119	10	☐Africa ☒Americas ☒Asia and Pacific ☒Europe ☐Middle East
WH211	Virus isolation ELISA	5	1	4	4	☐Africa ☐Americas ☒Asia and Pacific ☒Europe ☐Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
JAPAN	Advice on CSF/ASF real time PCR	Email advice discussion

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Investigation o immune mechanism induced by CSFV vaccine candidate	ongoing	To comare Imune responses induced by novel DIVA vaccine to live attenuated vaccines	CIBG Cuba	CUBA
characterisation of CSFV epitopes	ongoing	to characterise Epitopes of CSFV E2 protein	AHRI Taiwan	CHINESE TAIPEI

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

No

If the answer is no, please provide a brief explanation of the situation:
UK is free of CSFV

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:
The UK is free of CSFV

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 1
Head Start Immunity: Characterisation of the early protection of C strain vaccine against subsequent Swine fever virus infection

b) International conferences: 3
workshop on laboratory diagnosis and control of CSFV and ASFV, Madrid Spain 17-18 June 2019

2019 International Symposium of Classical swine fever 26-28 Oct 2019, Beijing China

Experience exchange on Prevention techniques and training course of Classical swine fever Chinese Taipei

Presentations
Learning from C strain to produce better vaccines

c) National conferences: 0

d) Other:
(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 1
b) Seminars: 0
c) Hands-on training courses: 0
d) Internships (>1 month): 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
a	CUBA	2

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO/IEC 17025:2005.	UKAS ISO17025-2005 Certificate of Accreditation.pdf
ISO 9001 2015	LRQA ISO9001-2015 Certificate Expiry 25-07-2020.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
CSF Virus Isolation	UKAS
CSFV ASFV RT-PCR	UKAS
CSFV Antibody ELISA	UKAS
Pestivirus serum neutralisation (comparative)	UKAS

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
Experience exchange on prevention techniques and training course of CSF diagnosis	11/19	Chinese taipei	speaker	learning from c strain to develop better vaccines
2019 International symposium of classical swine fever	10/19	China	speaker	Can C strain inform on how to generate better vaccines

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests: [1]	Role of your Reference Laboratory (organiser/ participant)	No. participants	Participating OIE Ref. Labs/ organising OIE Ref. Lab.
Proficiency testing of all tests used for serological and virological detection	participant	46	University of Veterinary Medicine of Hannover TiHo Germany (Organiser)

[1] *validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.*

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
Characterisation of monoclonal antibodies	characterisation of CSF Mabs binding diverse CSFV	Animal Health research institute (AHRI)

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

Purpose for inter-laboratory test comparisons[1]	No. participating laboratories	Region(s) of participating OIE Member Countries
PT0036 Detection of CSF antibodies by ELISA or neutralisation 9PT provider	16	☒Africa ☒Americas ☒Asia and Pacific ☒Europe ☐Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
Advice	UK	Answer to question on revision on OIE terrestrial manual chapter on CSF

25. Additional comments regarding your report: